RT Journal Article SR Electronic T1 COVID-19 in China: Risk Factors and R0 Revisited JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.18.20104703 DO 10.1101/2020.05.18.20104703 A1 Khan, Irtesam Mahmud A1 Zhang, Wenyi A1 Zafar, Sumaira A1 Wang, Yong A1 He, Junyu A1 Sun, Hailong A1 Haque, Ubydul A1 Rahman, M Sohel YR 2020 UL http://medrxiv.org/content/early/2020/05/22/2020.05.18.20104703.abstract AB The COVID-19 epidemic had spread rapidly through China and subsequently has proliferated globally leading to a pandemic situation around the globe. Human-to-human transmissions, as well as asymptomatic transmissions of the infection, have been confirmed. As of April 3rd’ public health crisis in China due to COVID-19 is potentially under control. We compiled a daily dataset of case counts, mortality, recovery, temperature, population density, and demographic information for each prefecture during the period of January 11 to April 07, 2020 (excluding Wuhan from our analysis due to missing data). Understanding the characteristics of spatiotemporal clustering of the COVID-19 epidemic and R0 is critical in effectively preventing and controlling the ongoing global pandemic. The prefectures were grouped based on several relevant features using unsupervised machine learning techniques. We performed a computational analysis utilizing the reported cases in China to estimate the revised R0 among different regions for prevention planning in an ongoing global pandemic. Finally, our results indicate that the impact of temperature and demographic (different age group percentage compared to the total population) factors on virus transmission may be characterized using a stochastic transmission model. Such predictions will help prioritize segments of a given community/region for action and provide a visual aid in designing prevention strategies for a specific geographic region. Furthermore, revised estimation and our methodology will aid in improving the human health consequences of COVID-19 elsewhere.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUH was supported by the Research Council of Norway (grant # 281077). Wenyi Zhang was partly supported by grants from the Chinese Major grant for the Prevention and Control of Infectious Diseases (No.2018ZX10733402-001-004, 2018ZX10713003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available at (https://github.com/rizvi23061998/estimate_chinese_r0) https://github.com/rizvi23061998/estimate_chinese_r0